Free Standard AU & NZ Shipping For All Book Orders Over $80!
Register      Login
Reproduction, Fertility and Development Reproduction, Fertility and Development Society
Vertebrate reproductive science and technology
RESEARCH ARTICLE

207 OOCYTE RECOVERY RATES AND IN VITRO BLASTOCYST PRODUCTION IN CATTLE TREATED WITH A SINGLE INJECTION OF FOLLTROPIN-V DILUTED IN A SLOW-RELEASE FORMULATION

F. L. Ongaratto A C , A. Tríbulo A C , M. Ramos A C , P. Rodriguez A C and G. A. Bó A B
+ Author Affiliations
- Author Affiliations

A Instituto de Reproducción Animal Córdoba (IRAC), General Paz, Córdoba, Argentina;

B Instituto de Ciencias Básicas, Carrera de Medicina Veterinaria, Universidad Nacional de Villa María, Villa del Rosario, Córdoba, Argentina;

C Facultad de Ciencias Agropecuarias, Universidad Nacional de Córdoba, Córdoba, Argentina

Reproduction, Fertility and Development 23(1) 202-203 https://doi.org/10.1071/RDv23n1Ab207
Published: 7 December 2010

Abstract

We have previously shown that superstimulation of beef donors with a single intramuscular (IM) injection of Folltropin-V (Bioniche Animal Health, Belleville, Ontario, Canada) diluted in a proprietary slow-release formulation (SRF; Bioniche Animal Health) results in in vivo embryo production comparable with the traditional twice-daily IM administration over 4 days (Tribulo et al. 2010 Reprod. Fertil. Dev. 22, 367). Two experiments were designed to evaluate oocyte recovery and in vitro blastocyst production of oocyte donors superstimulated with Folltropin-V, administered in twice-daily injections or diluted in SRF and given by a single injection. In Experiment 1, crossbred beef cows (n = 11) and heifers (n = 5) were randomly allocated to 3 treatment groups in a crossover design (i.e. all animals were treated 3 times, and all treatments were represented in the 3 replicates). All donors had all follicles >8 mm in diameter ablated by ultrasound-guided follicle aspiration on Day 0, received 500 μg of cloprostenol (prostaglandin F, Ciclase, Syntex, Argentina), and were treated as follows: Group 1 (multiple FSH): 160 mg of Folltropin-V divided into 4 IM injections administered twice daily (i.e. Days 1 and 2); Group 2 (single FSH): 160 mg of Folltropin-V diluted in 4 mL of 25% SRF and given by a single IM injection in the neck on Day 1; Group 3 (control): no FSH treatment. On Day 4, oocytes were aspirated from all follicles >3 mm in diameter by ultrasound-guided follicular aspiration, classified, matured in TCM-199 supplemented with 0.4% BSA, fertilized in Fert medium, and in vitro cultured in SOF supplemented with 0.4% BSA under oil at 37°C, 5% CO2, 5% O2, 90% N2, and saturated humidity for 7 days. Data were analyzed by ANOVA. The mean (±SEM) numbers of follicles aspirated and oocytes recovered were higher (P < 0.05) in Groups 1 (multiple FSH, 13.6 ± 1.9 and 8.5 ± 1.0) and 2 (single FSH, 14.7 ± 1.7 and 9.4 ± 1.3) than in Group 3 (control, 8.7 ± 0.9 and 5.8 ± 1.0). The mean number of blastocysts after 7 days in culture was numerically higher (P = 0.2) in Groups 1 (2.1 ± 0.7) and 2 (2.6 ± 0.6) than in Group 3 (1.1 ± 0.4). In Experiment 2, lactating Holstein cows (n = 10) received 2.5 mg of estradiol benzoate and 50 mg of progesterone IM on Day 0. On Day 4, all cows received prostaglandin F and were randomly allocated to 2 treatment groups, to receive 200 mg of Folltropin-V divided into 4 twice-daily IM injections or 200 mg of Folltropin-V diluted in 25% SRF and given as a single IM injection. On Day 7, oocytes were collected and treated like those in Experiment 1. The mean (±SEM) numbers of follicles aspirated (21.2 ± 3.5 and 14.4 ± 2.9), oocytes recovered (10.2 ± 1.2 and 13.8 ± 2.9), and blastocysts produced (4.6 ± 0.7 and 6.0 ± 2.0) did not differ for Groups 1 and 2, respectively (P = 0.3). In conclusion, superstimulatory treatment increased the number of cumulus–oocyte complexes available for IVF compared with no treatment, and ovarian superstimulatory treatment may be simplified by the use of a single IM dose of a sustained-release product, compared with multiple doses of a conventional product, without a reduction in the recovery or quality of cumulus–oocyte complexes.